Huaren Pharmaceutical Co., Ltd. Class A

Huaren Pharmaceutical Co., Ltd. Class A

SSZSE:300110
2.53
CNY
-0.04
(-1.56%)
-0.41EPS
3.75BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A carries a market capitalization of 3.75B, placing it among publicly traded companies globally. Its enterprise value stands at 4.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.75B
Enterprise Value4.83B

Share Statistics

As of September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A has 1.18B shares outstanding.

Shares Outstanding1.18B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.07, and the price-to-book ratio stands at 4.33.

PS Ratio3.07
PB Ratio4.33
P/TBV Ratio9.72

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.83B versus a market cap of 3.75B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.97

Financial Position

As of September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 133.63, indicating elevated leverage, while an interest coverage ratio of -12.81 demonstrates limited ability to service its debt obligations.

Current Ratio0.85
Quick Ratio0.19
Debt / Equity133.63
Debt / EBITDA-2.64
Interest Coverage-12.81

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -44.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -15.99, reflecting losses generated across the asset base. The company generates approximately 478,286.69 in revenue per employee across its workforce of 2,549.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.06 indicates how many times Huaren Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-44.54
Return on Assets (ROA)-15.99
Revenue Per Employee478,286.69
Employee Count2,549.00
Inventory Turnover3.06

Taxes

CNY

Over the twelve months ended September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A recorded 8.06M in income tax expense. The company reported a pretax loss of -479.12M and -490.57M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax8.06M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Huaren Pharmaceutical Co., Ltd. Class A's stock has declined approximately 30.11% over the past 52 weeks. The 50-day moving average sits at 2.88, while the 200-day moving average is 2.96.

52-Week Price Change-30.11%
50-Day Moving Average2.88
200-Day Moving Average2.96

Income Statement

CNY

Over the twelve months ended September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A generated 1.22B in revenue and converted that into -490.57M in net income, yielding earnings per share of -0.41. EBITDA reached -472.97M, while operating income came in at 136.55M.

Revenue1.22B
Gross Profit432.38M
Operating Income136.55M
Pretax Income-479.12M
Net Income-490.57M
EBITDA-472.97M
EBIT-472.97M
Earnings Per Share (EPS)-0.41

Balance Sheet

CNY

As of September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A holds 233.38M in cash and equivalents against 1.25B in total debt, resulting in a net debt position of 621.01M. Total book value stands at 864.80M, with working capital of -189.56M providing operational flexibility.

Cash & Cash Equivalents233.38M
Total Debt1.25B
Net Debt621.01M
Equity (Book Value)864.80M
Book Value Per Share0.73
Working Capital-189.56M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-19.98M

Margins

Over the twelve months ended September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A posted a gross margin of 35.47, reflecting its pricing power and cost economics. The operating margin of 11.20 and net profit margin of -40.24 provide insight into operational efficiency.

Gross Margin35.47
Operating Margin11.20
Pretax Margin-39.30
Profit Margin-40.24
EBITDA Margin-38.80

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A paid dividends of 0.03 per share. The dividend payout ratio of -6.85 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 6.59, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Huaren Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.03
Payout Ratio-6.85
Shareholder Yield6.59

Stock Splits

Huaren Pharmaceutical Co., Ltd. Class A's most recent stock split took place on February 9, 2018 with a 344:395 split ratio.

Last Split Date2/9/2018
Split Ratio344:395

Scores

As of September 30, 2026, Huaren Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 1.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.33